๐Ÿ”ฎForecastHer
Early Access โ€” Play-Money Beta

The Prediction Market for Women's Health & Culture

Sharp questions. Credible resolution. A community that actually knows the domain. Trade on what's next in femtech, fertility, wellness, policy, and culture.

6 markets proposedEvery market has a named resolution source

Pre-launch beta. Play money. Real money later pending approvals.

6 markets proposed ยท Every market has a named source

Pre-launch beta with play-money beta credits. Built for clear rules, clean sources, and transparent outcomes.

Market Preview

Real questions. Clear resolution criteria. Odds shown are illustrative โ€” real trading begins in beta.

๐Ÿ’„Culture

Will a major celebrity publicly share a menopause journey that goes viral in 2026?

76% Yes24% No

Resolves: A celebrity's menopause/perimenopause post reaches 1M+ engagements on any platform.

Closes Dec 31, 202615,230 beta credits
๐Ÿ’ŠWomen's Health

Will a new non-hormonal menopause treatment receive full FDA approval in 2026?

68% Yes32% No

Resolves: FDA grants full approval to a non-hormonal drug specifically for menopause symptoms. Verified via FDA.gov press releases.

Source: FDA.gov

Closes Dec 31, 202612,450 beta credits
๐Ÿ“ˆBusiness

Will women's longevity-focused interventions see a breakthrough funding round exceeding $100M in 2026?

62% Yes38% No

Resolves: A women's longevity startup raises >$100M in a single round, per Crunchbase or similar.

Closes Dec 31, 202611,200 beta credits
๐ŸŒฟWellness

Will microdosing GLP-1 drugs gain widespread use for PCOS management by end of 2026?

55% Yes45% No

Resolves: At least two major health systems or professional organizations recommend GLP-1 for PCOS management.

Closes Dec 31, 20269,870 beta credits
๐ŸผFertility

Will egg freezing costs drop below $8,000 average in the US by end of 2026?

42% Yes58% No

Resolves: Average cost tracked by FertilityIQ or similar authoritative source drops below $8,000.

Closes Dec 31, 20268,920 beta credits
๐Ÿ”ฌFemTech

Will AI-powered at-home diagnostics for endometriosis achieve clinical-grade accuracy in 2026?

35% Yes65% No

Resolves: A peer-reviewed study reports >90% sensitivity and specificity for an AI-based endometriosis diagnostic.

Closes Dec 31, 20266,340 beta credits

Resolution you can audit

Every market includes a clear resolve-by date, specific criteria that decides yes vs. no, a primary resolution source, and a public record of the outcome. We don't do vibes. We do rules.

📅

Resolve-by date

Every market has a deadline. No open-ended ambiguity.

Yes/No criteria

Specific conditions that decide the outcome. Published before trading opens.

🔗

Primary source

FDA.gov, Congress.gov, Crunchbase โ€” the source is named upfront.

📜

Public record

Resolution decisions are logged with the evidence used. Fully auditable.

How are markets resolved?+
We publish the resolution source and criteria up front. When the resolve date hits, we verify the outcome using the listed source and log the decision publicly.
Can anyone change the result?+
No. Resolution criteria and sources are locked once the market opens. The outcome is determined by the pre-stated rules, not by discretion.
Is this real money?+
Not yet. Beta uses play-money beta credits. Real-money markets will only launch after required regulatory approvals.

What we're optimizing for

These are the principles we evaluate every decision against.

Resolution clarity over volume

We'd rather have 20 markets with bulletproof criteria than 200 with vague rules. Every market should be resolvable by a stranger reading the criteria.

Sources you can check

Every market names its resolution source upfront. If the source isn't credible or verifiable, the market doesn't launch.

Domain expertise matters

Clinicians, researchers, patients, and advocates who follow women's health are better forecasters on these questions than the general public.

No fake activity

Zero volume means zero volume. We don't inflate numbers, invent users, or pretend the platform is busier than it is.

Play money first, earn trust

Real-money trading comes only after regulatory approvals and after we've proven the resolution process works. Track records first, stakes second.

Transparency by default

Resolution decisions, criteria changes, and platform updates are public. If we make a mistake, we publish the correction.

Why ForecastHer exists

Prediction markets are powerful because they reward people who see clearly. But most markets ignore the questions women actually care about โ€” and when they do show up, the resolution rules are often vague.

ForecastHer is building a better standard: markets designed around women's health, femtech, women's sports, culture, and consumer trends, with resolution criteria you can audit.

We're starting with play-money beta credits. Real money comes later, only after the proper approvals. The point right now is simple: build the most credible forecasting community for women-led topics on the internet.

Built by a team with experience in femtech, consumer health, and product growth.

Built with domain expertise

Markets live or die by trust. We care about sources, incentives, and resolution quality.

Product & Markets

People who have built consumer apps and community products at scale.

Women's Health & FemTech

Advisors with experience in women's health, clinical research, and femtech.

Compliance & Operations

Guidance from operators who understand regulatory reality and marketplace integrity.

We're recruiting advisors in women's health and market design. Want to help set the standard?

We're building with the community

Founding WallFirst 50 members, opt-in only
Community VoicesTop market proposers and referrers
Open RoadmapWhat we're building next, publicly

Get early access to the beta

Join the waitlist to get beta credits, propose markets, and earn a founding badge.

No spam. Just markets worth arguing about and resolving cleanly.